India has got another big success against the Corona epidemic. Bharat Biotech, a pharmaceutical company developing an indigenous vaccine in the country, has completed the Phase III trial of the nasal vaccine for use against the coronavirus. This vaccine from Bharat Biotech will be used through the nose and it can possibly be used for vaccination of young children or newborns. It is also being claimed that this nasal vaccine can be launched in the country soon. For this, approval is now awaited from the Drug Controller General of India (DCGI). After getting approval for emergency use of the vaccine from DCGI, it will be launched in the market.

While talking to news agency ANI, Dr Krishna Ella, Chairman and Managing Director (MD) of Bharat Biotech said that the third phase of the trial of Corona's nasal vaccine has been completed. He said that Bharat Biotech will submit the data related to the trial to the Drug Controller General of India for the use of this nasal vaccine in July. Dr. Ella further said that we have just completed a clinical trial and data analysis is going on on that. Next month we will submit the data to the Drugs Regulatory Agency. If all goes well, then we will get permission to launch and this will be the world's first vaccine to be used through the nose.

Let us inform that in January this year, the Drug Controller General of India had given approval to Bharat Biotech to start the third phase of trials related to the manufacture of nasal vaccine to be used against the coronavirus. Dr Krishna Aila, Chairman, Bharat Biotech, said that the results of the Phase III trial of this nasal vaccine are as expected and this nasal vaccine can prove to be a huge game-changer against the corona epidemic.

Dr. Krishna Aila, Chairman, Bharat Biotech has claimed that our nasal vaccine is a game-changer, as it will not only protect people from dangerous virus infection but will also prevent the spread of the virus. He said that for this we have signed an agreement with Washington University School of Medicine in St. Louis. He claimed that this nasal vaccine largely builds up the immune system in the human body and inhibits the production of IgG, mucosal IgA and T cells. He said that the coronavirus usually spreads the infection through the nose. This nasal vaccine is capable of preventing virus infection and its spread by strengthening the immune system in the nasal mucosa itself.